Forteo 250 mcg (Teriparatide SOLUTION) 250 MCG

FORTEO 250 MCG is a subcutaneous solution containing teriparatide, used to support bone health. This medication is designed to help improve bone density and reduce fracture risk.

Strength

250 MCG

Pack Size

3ML PEN

Manufacturer / TM Owner

ELI LILLY CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

FORTEO 250 MCG is primarily used to treat conditions related to bone loss, such as osteoporosis. It works by stimulating bone formation, which can help strengthen bones and reduce the likelihood of fractures. This medication is often prescribed for individuals who have a high risk of bone fractures or those who have not responded well to other treatments.

Side Effects

Common effects of FORTEO 250 MCG may include mild discomfort at the injection site, dizziness, or nausea. Some users may also experience headaches or leg cramps. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

Precautions & Warnings

FORTEO 250 MCG should be stored properly to maintain its effectiveness. It is important to follow the storage instructions provided with the medication. Additionally, this medication should be used with caution in individuals with a history of certain medical conditions, such as bone cancer or Paget's disease.

Avoid Interactions

FORTEO 250 MCG may interact with other medications, including those that affect bone metabolism. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare provider, as it may affect the effectiveness of the medication.

Frequently Asked Questions

FORTEO 250 MCG is used to treat conditions related to bone loss, such as osteoporosis, by stimulating bone formation.

FORTEO 250 MCG is administered via subcutaneous injection, typically in the thigh or abdomen.

Common side effects may include mild discomfort at the injection site, dizziness, nausea, headaches, or leg cramps.

FORTEO 250 MCG may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

FORTEO 250 MCG should be stored according to the instructions provided with the medication to maintain its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.